DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
email sent successfully
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
The New England Journal of Medicine Publishes Comprehensive Data From Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (Teprotumumab-Trbw) for Thyroid Eye Disease
Horizon Therapeutics plc announced that The New England Journal of Medicine has published comprehensive results of the Phase 3 OPTIC clinical trial evaluating TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease (TED). OPTIC is part of the largest clinical program in TED and demonstrates that TEPEZZA provides significant improvements in proptosis (eye bulging) and diplopia (double vision) compared to placebo.
TEPEZZA is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) that is administered to patients once every three weeks for a total of eight infusions. TEPEZZA was approved by the U.S. Food and Drug Administration (FDA) on January 21, 2020 – making it the first and only medicine approved for the treatment of TED. The medicine received Priority Review, Orphan Drug, Fast Track and Breakthrough Therapy designations from the FDA.
More from Teprotumumab News:
FDA Approves First Treatment for Thyroid Eye Disease (Teprotumumab)
Teprotumumab Significantly Improves Proptosis in Thyroid eye Disease
Clinical Trial Analyses Substantiate that Teprotumumab Improves Debilitating Effects of TED
FDA Grants Priority Review of Teprotumumab Biologics License Application for the Treatment of TED
More from Teprotumumab Research:
Teprotumumab for the Treatment of Active Thyroid Eye Disease
(Authors: Raymond S. Douglas, George J. Kahaly et. al.)
Teprotumumab in the Treatment of Active TED: A Focus on Proptosis
(Author: Raymond S. Douglas)
Evidence & EducationEfficacy of Orbital Radiotherapy in Moderate-to-Severe Active Graves’ Orbitopathy Including Long-Lasting Disease: ...Background: We aimed to explore the eff...
Evidence & EducationHyperthyroidism: Graves’ OphthalmopathyGraves' ophthalmopathy, also called thyr...
People & PlacesBrian Chuck Tse, MDBrian Chuck Tse is an Assistant Professo...
Evidence & EducationRehabilitative Orbital Decompression for Graves’ Orbitopathy: Results of a Randomized Clinical TrialPurpose: Orbital decompression (OD) is ...
News & MeetingsDealing With Thyroid Eye Disease: Patient and Physician PerspectivesJoin us for a webinar hosted by the Grav...
Evidence & EducationWhich Factors are Associated With Quality of Life in Patients With Graves’ Orbitopathy Presenting for Orbital ...Purpose: Graves' orbitopathy (GO) is as...
Evidence & EducationA Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients With Minimally Active Grav...Context: Radioiodine is an effective an...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.